Quince Therapeutics presents inhaled rapamycin at Cantor conference
UKPulse Markets Desk
Quince Therapeutics presented its inhaled rapamycin programme at a Cantor conference, with the source describing the treatment as gaining traction.
- Quince Therapeutics appeared at a Cantor conference.
- The company's inhaled rapamycin programme was the subject of the presentation.
- The source describes inhaled rapamycin as gaining traction.
Quince Therapeutics presented at a Cantor conference, where its inhaled rapamycin programme was the focus, according to a report from Investing.com UK.
The report describes inhaled rapamycin as gaining traction. No further details of the presentation, including figures, dates or commentary, were available in the source material.